Search

Your search keyword '"Suoyu Xu"' showing total 22 results

Search Constraints

Start Over You searched for: Author "Suoyu Xu" Remove constraint Author: "Suoyu Xu"
22 results on '"Suoyu Xu"'

Search Results

1. Impact of drug distribution into adipose on tissue function: The cholesteryl ester transfer protein (CETP) inhibitor anacetrapib as a test case

2. Impact of drug distribution into adipose on tissue function: The cholesteryl ester transfer protein (CETP) inhibitor anacetrapib as a test case

3. Analysis of the volatile components of tea seed oil (Camellia sinensis O. Ktze) from China using HS-SPME-GC/MS

4. Characterization of Anacetrapib Distribution into the Lipid Droplet of Adipose Tissue in Mice and Human Cultured Adipocytes

5. Discovery and optimization of orally active cyclohexane-based prolylcarboxypeptidase (PrCP) inhibitors

6. Discovery of benzodihydroisofurans as novel, potent, bioavailable and brain-penetrant prolylcarboxypeptidase inhibitors

7. Discovery of aminoheterocycles as potent and brain penetrant prolylcarboxypeptidase inhibitors

8. Discovery of benzimidazole pyrrolidinyl amides as prolylcarboxypeptidase inhibitors

9. A strategy of employing aminoheterocycles as amide mimics to identify novel, potent and bioavailable soluble epoxide hydrolase inhibitors

10. Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors

11. Impact of drug distribution into adipose on tissue function: The cholesteryl ester transfer protein (CETP) inhibitor anacetrapib as a test case.

12. Reply to: Ahren B et al. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab 2011; 13(9): 775-783 and Ahren B et al. Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. Diabetes Obes Metab 2011; 13(3): 193-203

13. A new class of prolylcarboxypeptidase inhibitors, part 1: discovery and evaluation

14. A new class of prolylcarboxypeptidase inhibitors, part 2: the aminocyclopentanes

15. Discovery of a new class of potent prolylcarboxypeptidase inhibitors derived from alanine

16. The discovery of non-benzimidazole and brain-penetrant prolylcarboxypeptidase inhibitors

17. Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement

18. Utility of unbound plasma drug levels and P-glycoprotein transport data in prediction of central nervous system exposure

19. Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors

20. (2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: a selective alpha-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

21. High throughput metabolic stability screen for lead optimization in drug discovery

Catalog

Books, media, physical & digital resources